Illumina Can't Escape $115M Judgment In Syntrix Patent Suit

Law360, New York (November 4, 2013, 10:33 PM EST) -- A Washington state federal judge on Monday refused to overturn a $115 million jury verdict in a patent infringement suit against Illumina Inc., finding Syntrix Biosystems had presented sufficient evidence that Illumina violated a patent covering DNA technology.

U.S. District Judge Benjamin H. Settle rejected Illumina's challenge to the evidence on claim limitations and also found biotechnology research firm Syntrix had shown that its U.S. Patent No. 6,951,682 was entitled to a priority date before the prior art references asserted by Illumina.

Illumina claims its allegedly...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.